2 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Source The Motley Fool

Are there misconceptions about investing? You bet there are. One of the biggest, in my opinion, is that you need a lot of money to get started. That's not true at all.

You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare sector, it's an especially easy task. Here are two no-brainer healthcare stocks to buy with $200 right now.

Pfizer: A better story than meets the eye

I can imagine some eyes might be rolling seeing Pfizer (NYSE: PFE) listed. The pharma stock has plunged over 50% from its peak and is barely in positive territory in 2024. Pfizer faces several challenges, including sinking COVID-19 vaccine sales and the looming patent expirations for several top products. However, I think there's a better story with Pfizer than meets the eye.

First, Pfizer is cheap. I'm not just talking about the drugmaker's share price of under $30. The stock trades at a forward price-to-earnings ratio of 10.2. The forward earnings multiple for the S&P 500 healthcare sector is 18.5.

Income investors should love Pfizer's forward dividend yield of 5.75%. I think other investors should like this juicy yield too, because it gives Pfizer a big advantage in delivering exceptional total returns.

Pfizer's growth outlook should improve significantly in the coming years, too. I don't expect the company's COVID-19 vaccine sales to ever return to their lofty levels of 2021 and 2022. And Pfizer won't be able to escape the negative impact of its patent cliff. However, the company's acquisitions in recent years and pipeline development should pay off.

One good example of the former is Pfizer's 2022 acquisition of Biohaven Pharmaceuticals. This deal added migraine drug Nurtec to Pfizer's lineup. In the second quarter of 2024, sales for Nurtec soared 44% year over year.

An example of the latter is Pfizer's investment in developing respiratory syncytial virus (RSV) vaccine Abrysvo. Management expects the vaccine to generate peak annual sales of over $2 billion.

Activist investor Starboard Value, which recently invested close to $1 billion in Pfizer, might not agree with this bullish take. However, I see Starboard's involvement in Pfizer as a positive, especially with the company reportedly enlisting former Pfizer CEO Ian Read and former CFO Frank D'Amelio in its efforts.

TransMedics Group: An organic growth machine in more ways than one

TransMedics Group (NASDAQ: TMDX) is in a much different place than Pfizer. This up-and-coming company is turning the organ transplant market upside down with its Organ Care System (OCS), which keeps donor livers, hearts, and lungs functioning until they can make it to their intended recipients.

Business is booming for TransMedics. In Q2, revenue soared 118% year over year to $114.3 million. The company reported another profitable quarter with earnings of $12.2 million compared to a net loss of $1 million in the prior-year period.

Cold storage has been the standard for transporting donor organs in the past. However, far too many organs didn't make it to recipients in an acceptable condition to be used. This massive underutilization of donor organs presents a big opportunity for TransMedics.

There's even more good news, though. OCS dramatically reduces the number of severe post-transplant complications with organ transplants -- 50% for lungs, 65% for hearts, and 43% for livers.

TransMedics is also addressing another major obstacle for organ transplants: the lack of availability of aircraft to transport donor organs. The company acquired private charter operator Summit Aviation last year to establish the first air logistics provider in the U.S. dedicated exclusively to organ transplantation.

I expect TransMedics' growing fleet of aircraft will enable it to expand the U.S. organ transplant market. The company is also pursuing reimbursement coverage for OCS in key European markets. With a share price of around $135, investors can afford to buy TransMedics and Pfizer with $200 and have money left over.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $20,579!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,710!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $389,239!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of October 7, 2024

Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer and TransMedics Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
23 hours ago
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
23 hours ago
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
Author  Irene Q.
23 hours ago
The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
22 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
22 hours ago
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
goTop
quote